Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04090710
Title SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ontario Clinical Oncology Group (OCOG)
Indications

renal cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior | adult | child
Covered Countries CAN

Facility Status City State Zip Country Details
Peter MacCallum Cancer Centre Recruiting Melbourne 3000 Australia Details
Cross Cancer Institute Recruiting Edmonton Alberta T6G 1Z2 Canada Details
Juravinski Cancer Centre Recruiting Hamilton Ontario Canada Details
Grand River Regional Cancer Centre Recruiting Kitchener Ontario N2G1G3 Canada Details
London Regional Cancer Centre Withdrawn London Ontario N2G1G3 Canada Details
The Ottawa Regional Cancer Centre Recruiting Ottawa Ontario K1H8L6 Canada Details
Sunnybrook Health Sciences Centre- Odette Cancer Centre Recruiting Toronto Ontario M4N3M5 Canada Details
McGill University Health Centre - Glen site Not yet recruiting Montréal Quebec Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field